Quick Answer
Edgewise Therapeutics, Inc. reported Net Income of -$167.79 million for fiscal year 2025.
Edgewise Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$167.79M -25.4% |
-$133.81M -33.6% |
-$100.16M -48.1% |
-$67.64M -58.0% |
-$42.81M -150.0% |
-$17.12M |
| Diluted EPS | -$1.63 -12.4% |
-$1.45 +7.6% |
-$1.57 | — | — | — |
| Total Assets | $552.60M +13.5% |
$486.82M +43.2% |
$340.04M -7.4% |
$367.10M +28.7% |
$285.23M +117.5% |
$131.14M |
| Cash and Equivalents | $61.15M +46.8% |
$41.67M -51.6% |
$86.10M +291.5% |
$21.99M +41.3% |
$15.57M -85.2% |
$104.92M |
| Stockholders Equity | $522.26M +13.7% |
$459.22M +44.0% |
$318.83M -8.0% |
$346.72M +26.4% |
$274.38M +921.0% |
-$33.42M -98.3% |
| R&D Expense | $151.39M +19.2% |
$126.97M +39.7% |
$90.91M +68.2% |
$54.03M +67.9% |
$32.19M +114.8% |
$14.98M |
| Operating Income | -$191.41M -20.5% |
-$158.83M -38.9% |
-$114.36M -59.6% |
-$71.66M -65.8% |
-$43.22M -151.4% |
-$17.19M |
| Shares Outstanding | 106.25M +12.0% |
94.84M +34.6% |
70.45M +11.4% |
63.26M +27.8% |
49.50M +4803.6% |
1.01M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$40.67M | -19.2% | -12.6% |
| Total Assets | September 30, 2025 | $583.47M | +14.1% | -4.9% |
| Cash and Equivalents | September 30, 2025 | $46.00M | +2.7% | +6.0% |
| Long-Term Debt | September 30, 2022 | $59.0K | — | — |
| Stockholders Equity | September 30, 2025 | $558.65M | +14.3% | -5.2% |
| R&D Expense | September 30, 2025 | $37.48M | +16.3% | +11.7% |
| Operating Income | September 30, 2025 | -$46.86M | -15.9% | -10.0% |
| Shares Outstanding | September 30, 2025 | 105.76M | +12.0% | +0.4% |
- Edgewise Therapeutics, Inc. reported Net Income of -$167.79 million for fiscal year 2025.
- Edgewise Therapeutics, Inc. showed a decrease of -25.4% in Net Income compared to the prior fiscal year.
- Edgewise Therapeutics, Inc. reported Diluted EPS of $1.63 per share (loss) for fiscal year 2025.
- Edgewise Therapeutics, Inc. showed a decrease of -12.4% in Diluted EPS compared to the prior fiscal year.
- Edgewise Therapeutics, Inc. reported Total Assets of $552.60 million for fiscal year 2025.
- Edgewise Therapeutics, Inc. showed an increase of +13.5% in Total Assets compared to the prior fiscal year.
- Edgewise Therapeutics, Inc. reported Cash and Equivalents of $61.15 million for fiscal year 2025.
- Edgewise Therapeutics, Inc. showed an increase of +46.8% in Cash and Equivalents compared to the prior fiscal year.
- Edgewise Therapeutics, Inc. reported Stockholders Equity of $522.26 million for fiscal year 2025.
- Edgewise Therapeutics, Inc. showed an increase of +13.7% in Stockholders Equity compared to the prior fiscal year.
- Edgewise Therapeutics, Inc. reported R&D Expense of $151.39 million for fiscal year 2025.
- Edgewise Therapeutics, Inc. showed an increase of +19.2% in R&D Expense compared to the prior fiscal year.
- Edgewise Therapeutics, Inc. reported Operating Income of -$191.41 million for fiscal year 2025.
- Edgewise Therapeutics, Inc. showed a decrease of -20.5% in Operating Income compared to the prior fiscal year.
- Edgewise Therapeutics, Inc. reported Shares Outstanding of 106.25 million shares for fiscal year 2025.
- Edgewise Therapeutics, Inc. showed an increase of +12.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: